Compare JELD & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JELD | PMN |
|---|---|---|
| Founded | 1960 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Forest Products | Pharmaceuticals and Biotechnology |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.7M | 115.5M |
| IPO Year | 2016 | 2022 |
| Metric | JELD | PMN |
|---|---|---|
| Price | $1.47 | $10.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.43 | ★ $42.67 |
| AVG Volume (30 Days) | ★ 1.7M | 29.6K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $0.29 |
| 52 Week High | $6.98 | $27.40 |
| Indicator | JELD | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 40.33 |
| Support Level | $1.25 | $9.31 |
| Resistance Level | $2.06 | $13.80 |
| Average True Range (ATR) | 0.15 | 0.56 |
| MACD | -0.02 | 0.17 |
| Stochastic Oscillator | 38.39 | 54.34 |
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.